Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL205 in advanced solid tumors
ChiCTR2400084741Phase 2Not yet recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of YL205 in Nonhematologic neoplasms, ovarian cancer, Non-small cell lung cancer (NS-NSCLC) and 2 more, sponsored by Jilin Provincial Cancer Hospital. Primary endpoints: Objective response rate, Adverse events and 3 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
YL205
03
Conditions
Nonhematologic neoplasmsovarian cancerNon-small cell lung cancer (NS-NSCLC)endometrial cancer (EC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2400084741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084741.